文献速递神经核医学肿瘤 PET/CT

无强化脑肿瘤的FDOPA PET-CT显像

FDOPA PET-CT of Nonenhancing Brain Tumors.
PubMed 文献 · Clin Nucl Med · 2017-01-01

本研究前瞻性纳入53例MRI无对比增强的组织学证实胶质瘤患者(35例低级别、18例高级别),评估FDOPA PET对肿瘤侵袭性的诊断价值。FDOPA可用于低级别胶质瘤亚组中鉴别胚胎发育不良性神经上皮肿瘤与II级少突胶质细胞瘤(P<0.01);SUVmax(T/N)30=2.16为鉴别低级别与高级别胶质瘤的最佳阈值,灵敏度60%、特异度100%、PPV 100%、NPV 83.33%(P<0.01)。MRSI代谢物比值在高级别胶质瘤中显著高于低级别,且与SUVmax呈显著正相关。

要点

  • FDOPA PET可在MRI无强化的低级别胶质瘤中鉴别胚胎发育不良性神经上皮肿瘤与II级少突胶质细胞瘤(P<0.01)。
  • SUVmax(T/N)30=2.16鉴别低级别与高级别胶质瘤的灵敏度60%、特异度100%、PPV 100%、NPV 83.33%。
  • MRSI的nCho/Cr与nCho/NAA比值在高级别胶质瘤中显著高于低级别(P<0.03与P<0.04)。

核心结论

  • 氨基酸代谢数据单独使用或与MRSI联合,可鉴别胚胎发育不良性神经上皮肿瘤与II级少突胶质细胞瘤,并可鉴别MRI无对比增强的低级别与高级别胶质瘤。

研究设计与样本

  • 前瞻性纳入53例组织学证实的胶质瘤患者,其中低级别35例、高级别18例,MRI均无对比增强。
  • 每例患者均行30分钟静态PET采集,并均行MRSI测量不同代谢物比值。

主要发现

  • FDOPA在低级别胶质瘤亚组中有用,可鉴别胚胎发育不良性神经上皮肿瘤与II级少突胶质细胞瘤(P<0.01)。
  • SUVmax(T/N)30=2.16为鉴别低级别与高级别胶质瘤的最佳阈值,灵敏度60%、特异度100%、PPV 100%、NPV 83.33%(P<0.01)。
  • nCho/Cr与nCho/NAA比值在高级别胶质瘤中显著高于低级别胶质瘤(P<0.03与P<0.04)。
  • MRSI比值与SUVmax之间呈显著正相关。

关键数值与推荐

  • SUVmax(T/N)30=2.16为鉴别低级别与高级别胶质瘤的最佳阈值,灵敏度60%、特异度100%、PPV 100%、NPV 83.33%(P<0.01)。
  • nCho/Cr与nCho/NAA比值在高级别较低级别胶质瘤显著升高(P<0.03与P<0.04)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary brain tumor grading is crucial to rapidly determine the therapeutic impact and prognosis of a brain tumor as well as the tumors' aggressiveness profile. On magnetic resonance imaging, high-grade tumors are usually responsible for blood -brain barrier breakdowns, which result in tumor enhancement. However, this is not always the case. The main objective of this study was to evaluate the diagnostic value of FDOPA PET in the assessment of primary brain tumor aggressiveness with no contrast enhancement on MRI. METHODS: Fifty-three patients were prospectively included: 35 low-grade and 18 high-grade histologically proven gliomas, with no contrast enhancement. Each patient underwent static PET acquisitions at 30 minutes. All patients had MRSI with measurements of different metabolites ratio. RESULTS: FDOPA was useful in the subgroup of low-grade gliomas, discriminating between dysembryoplastic neuroepithelial tumor and grade II oligodendroglioma (P < 0.01). An optimal threshold of the maximum standardized uptake value at 30 minutes (SUVmax (T/N)30) = 2.16 to discriminated low- from high-grade gliomas with a sensitivity of 60%, specificity of 100%, PPV of 100%, and NPV of 83.33% (P < 0.01). The nCho/Cr and nCho/NAA ratios were significantly higher in high- than in low-grade gliomas (P < 0.03 and P < 0.04, respectively). A significant positive correlation between MRSI ratios and SUVmax was found. CONCLUSION: Including data from amino acid metabolism used alone or in association with MRSI allows us to discriminate between dysembryoplastic neuroepithelial tumor and grade II oligodendroglioma and between low- and high-grade gliomas with no contrast enhancement on MRI.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Bund C, Heimburger C, Imperiale A, et al. FDOPA PET-CT of Nonenhancing Brain Tumors. Clin Nucl Med. 2017. PMID: 28114224. doi:10.1097/RLU.0000000000001540

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。